Astaxanthin Ameliorates Doxorubicin-Induced Cognitive Impairment (Chemobrain) in Experimental Rat Model: Impact on Oxidative, Inflammatory, and Apoptotic Machineries
- 2.4k Downloads
Chemobrain refers to a common sequelae experienced by 15–80% of cancer patients exposed to chemotherapeutics. The antineoplastic agent doxorubicin (DOX) has been implicated in a strenuous neurotoxicity manifested as decline in cognitive functions, most probably via cytokine-induced oxidative and nitrosative damage to brain tissues. Astaxanthin (AST), a naturally occurring carotenoid, is reputable for its outstanding antioxidant, anti-inflammatory, and antiapoptotic activities. Therefore, the aim of the current study was to investigate the potential neuroprotective and memory-enhancing effects of AST against DOX-induced behavioral and neurobiological abnormalities. Briefly, AST treatment (25 mg/kg) significantly protected against DOX-induced memory impairment. Furthermore, AST restored hippocampal histopathological architecture, halted DOX-induced oxidative and inflammatory insults, mitigated the increase in acetylcholinesterase activity, and consistently downregulated the overactive apoptotic machineries. In conclusion, these findings suggest that AST offers neuroprotection against DOX-induced cognitive impairment which could be explained at least partly by its antioxidant, anti-inflammatory, and antiapoptotic effects.
KeywordsChemobrain Doxorubicin Astaxanthin Oxidative stress Neuroinflammation Apoptosis
Compliance with Ethical Standards
The experimental protocol including procedures of laboratory animal care in research was approved by the Research Ethics Committee, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt, under the memorandum no. 87.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.Olin JJ. Cognitive function after systemic therapy for breast cancer. Oncology (Williston Park). 2001;15(5):613–618; discussion 618, 621–624. http://www.ncbi.nlm.nih.gov/pubmed/11396356. Accessed July 30, 2016.
- 7.Aluise CD, Sultana R, Tangpong J et al (2010) Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. In:147–156. https://doi.org/10.1007/978-1-4419-6306-2_19
- 9.Volkova M, Russell R, III. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011;7(4):214–220. doi: https://doi.org/10.2174/157340311799960645.
- 12.Jansen CE, Dodd MJ, Miaskowski CA, Dowling GA, Kramer J (2008) Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology 17(12):1189–1195. https://doi.org/10.1002/pon.1342 CrossRefPubMedGoogle Scholar
- 13.Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11):2292–2299. https://doi.org/10.1002/cncr.20272 CrossRefPubMedGoogle Scholar
- 16.Cardoso S, Santos RX, Carvalho C et al (2008) Doxorubicin increases the susceptibility of brain mitochondria to Ca(2+)-induced permeability transition and oxidative damage. Free Radic Biol Med 45(10):1395–1402. https://doi.org/10.1016/j.freeradbiomed.2008.08.008 CrossRefPubMedGoogle Scholar
- 19.Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol. 2008;101(10, Supplement 1):S58-S68. doi: https://doi.org/10.1016/j.amjcard.2008.02.010.
- 20.Lee S-J, Bai S-K, Lee K-S et al (2003) Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cells 16(1):97–105 http://www.ncbi.nlm.nih.gov/pubmed/14503852. Accessed April 26, 2017PubMedCrossRefGoogle Scholar
- 30.Kitamura Y, Hattori S, Yoneda S et al (2015) Doxorubicin and cyclophosphamide treatment produces anxiety-like behavior and spatial cognition impairment in rats: possible involvement of hippocampal neurogenesis via brain-derived neurotrophic factor and cyclin D1 regulation. Behav Brain Res 292:184–193. https://doi.org/10.1016/j.bbr.2015.06.007 CrossRefPubMedGoogle Scholar
- 32.KIM J-H, CHOI S-K, CHOI S-Y, KIM H-K, CHANG H-I (2005) Suppressive effect of astaxanthin isolated from the Xanthophyllomyces dendrorhous mutant on ethanol-induced gastric mucosal injury in rats. Biosci Biotechnol Biochem 69(7):1300–1305. https://doi.org/10.1271/bbb.69.1300 CrossRefPubMedGoogle Scholar
- 33.Abdel-Aziz AK, Mantawy EM, Said RS, Helwa R (2016) The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries. Exp Neurol 283:129–141. https://doi.org/10.1016/j.expneurol.2016.06.004. CrossRefPubMedGoogle Scholar
- 34.Bancroft JD (2008) Gamble M. Theory and practice of histological techniques, Churchill Livingstone/ElsevierGoogle Scholar
- 36.Menze ET, Esmat A, Tadros MG, Abdel-Naim AB, Khalifa AE. Genistein improves 3-NPA-induced memory impairment in ovariectomized rats: impact of its antioxidant, anti-inflammatory and acetylcholinesterase modulatory properties. Blum D, ed. PLoS One 2015;10(2):e0117223. doi: https://doi.org/10.1371/journal.pone.0117223.
- 40.Xu L, Zhu J, Yin W, Ding X (2015) Astaxanthin improves cognitive deficits from oxidative stress, nitric oxide synthase and inflammation through upregulation of PI3K/Akt in diabetes rat. Int J Clin Exp Pathol 8(6):6083–6094 http://www.ncbi.nlm.nih.gov/pubmed/26261486. Accessed February 23, 2017PubMedPubMedCentralGoogle Scholar
- 43.Joshi G, Aluise CD, Cole MP et al (2010) Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain. Neuroscience 166(3):796–807. https://doi.org/10.1016/j.neuroscience.2010.01.021 CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Joshi G, Hardas S, Sultana R, St Clair DK, Vore M, Butterfield DA (2007) Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: implication for chemobrain. J Neurosci Res 85(3):497–503. https://doi.org/10.1002/jnr.21158 CrossRefPubMedGoogle Scholar
- 52.Butler M, O’Connor J, Moynagh P (2004) Dissection of tumor-necrosis factor-α inhibition of long-term potentiation (LTP) reveals a p38 mitogen-activated protein kinase-dependent mechanism which maps to early—but not late—phase LTP. Neuroscience 124(2):319–326. https://doi.org/10.1016/j.neuroscience.2003.11.040 CrossRefPubMedGoogle Scholar
- 53.Keeney J. Doxorubicin-induced, TNF-α-mediated brain oxidative stress, neurochemical alterations, and cognitive decline: insights into mechanisms of chemotherapy induced cognitive impairment and its prevention. Theses Diss. 2013. http://uknowledge.uky.edu/chemistry_etds/27. Accessed April 26, 2017.
- 65.Choi S-K, Park Y-S, Choi D-K, Chang H-I (2008) Effects of astaxanthin on the production of NO and the expression of COX-2 and iNOS in LPS-stimulated BV2 microglial cells. J Microbiol Biotechnol 18(12):1990–1996 http://www.ncbi.nlm.nih.gov/pubmed/19131704. Accessed August 28, 2016PubMedGoogle Scholar
- 71.Dose J, Matsugo S, Yokokawa H et al (2016) Free radical scavenging and cellular antioxidant properties of astaxanthin. Int J Mol Sci 17(1). https://doi.org/10.3390/ijms17010103
- 72.Tangpong J, Miriyala S, Noel T, Sinthupibulyakit C, Jungsuwadee P, St Clair DK (2011) Doxorubicin-induced central nervous system toxicity and protection by xanthone derivative of Garcinia mangostana. Neuroscience 175:292–299. https://doi.org/10.1016/j.neuroscience.2010.11.007 CrossRefPubMedGoogle Scholar
- 74.Li J, Xia Y, Liu T, et al. Protective effects of astaxanthin on ConA-induced autoimmune hepatitis by the JNK/p-JNK pathway-mediated inhibition of autophagy and apoptosis. Papa S, ed. PLoS One 2015;10(3):e0120440. https://doi.org/10.1371/journal.pone.0120440.
- 75.Usta Y, Ismailoglu U, Bakkaloglu A et al (2004) Effects of pentoxifylline in adriamycin-induced renal disease in rats. Pediatr Nephrol 19(8). https://doi.org/10.1007/s00467-004-1538-5